Department of Oncology and Hematology, BMT with Section Pneumology, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hubertus Wald Tumorzentrum, Martinistrasse 52, 20246 Hamburg, Germany.
Cancer Immunol Immunother. 2012 Oct;61(10):1639-51. doi: 10.1007/s00262-012-1220-x. Epub 2012 Feb 21.
Myeloma patients may develop oligoclonal immunoglobulins, so-called abnormal protein bands (APB), after stem cell transplantation. APB do not correspond to the patient's paraprotein and confer a good prognosis. We set out to investigate whether such APB represent a humoral anti-myeloma immune response by screening immunoglobulins of 15 myeloma patients after allogeneic stem cell transplantation and a control group of healthy donors for reactivity with myeloma protein extracts. While the immunoglobulins of healthy donors did not react with myeloma protein extracts, patient-derived immunoglobulins showed variable levels of interaction, depending on the presence of APB on immunofixation. Most commonly, we detected interactions with heat-shock proteins, followed by neutral alpha-glucosidase, alpha-enolase and vimentin, as well as proliferating cell nuclear antigen and MAGEA4. More than 80% of targets were upregulated in myeloma. Heat-shock protein 60 (HSP60) was subsequently evaluated as an exemplary antigen. We found that HSP60 was aberrantly displayed on the surface of primary myeloma cells. Indeed, patient-derived APB-containing immunoglobulins recognized surface HSP60 suggesting that this antigen becomes accessible to the immune system after aberrant membrane exposition. We conclude that immunoglobulin fractions with APB recognize recurrent myeloma antigens and that this humoral response may contribute to the more favorable prognosis in patients with APB.
骨髓瘤患者在干细胞移植后可能会产生寡克隆免疫球蛋白,即所谓的异常蛋白带(APB)。APB 与患者的副蛋白不对应,并预示着良好的预后。我们着手研究这些 APB 是否代表体液性抗骨髓瘤免疫反应,为此我们筛选了 15 名接受异基因干细胞移植后的骨髓瘤患者和一组健康供者的免疫球蛋白,以检测其与骨髓瘤蛋白提取物的反应性。虽然健康供者的免疫球蛋白与骨髓瘤蛋白提取物没有反应,但患者来源的免疫球蛋白表现出不同程度的相互作用,这取决于免疫固定上是否存在 APB。最常见的是,我们检测到与热休克蛋白、中性α-葡萄糖苷酶、α-烯醇酶和波形蛋白以及增殖细胞核抗原和 MAGEA4 的相互作用。超过 80%的靶标在骨髓瘤中上调。随后,我们选择热休克蛋白 60(HSP60)作为代表性抗原进行评估。我们发现 HSP60 异常地表现在原发性骨髓瘤细胞表面。事实上,含有 APB 的患者来源的免疫球蛋白能够识别表面 HSP60,这表明该抗原在异常的膜暴露后可被免疫系统识别。我们的结论是,具有 APB 的免疫球蛋白片段可识别复发性骨髓瘤抗原,并且这种体液反应可能有助于 APB 患者的预后更有利。